siRNA therapeutics for ocular disease/dermatological disease (Phio Pharmaceuticals)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NamesiRNA therapeutics for ocular disease/dermatological disease (Phio Pharmaceuticals)
Drug Alias NamesiRNA therapeutics for ocular disease/dermatological disease (RXi Pharmaceuticals)siRNA therapeutics for ocular disease(RXi Pharmaceuticals)siRNA therapeutics for ocular disease(Galena Biopharma)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionPeptidylprolyl isomerase inhibitorsMitogen-activated protein kinase kinase kinase kinase 4 inhibitors
TargetsPeptidylprolyl isomeraseMitogen-activated protein kinase kinase kinase kinase 4
Therapy Area/IndicationsSkin DiseasesEye Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSellas Life Sciences Group Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMemorial Sloan Kettering Cancer CenterUniversity Of Massachusetts Medical SchoolSellas Life Sciences Group Inc +[4] 
Active IndicationsN/A
Inactive IndicationsSkin DiseasesEye Diseases

Other Information

ATC CodeN/A
Related LinksN/A